Search Results
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
combination with osimertinib as a first-line therapy for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).In June 2026, MAIA Biotechnology announced the activation of Winship Cancer Institute of Emory University as the third U.S. site in its Phase 2 THIO-101 expansion
More news about: DelveInsight Business Research, LLP
Jun 21, 2026, 22:26 ET El polvo fino Daicel DURAST® POM adoptado para lubricante innovador en formato barra
ingeniería, ha anunciado que su polvo fino DURAST® POM se ha adoptado para su uso en un innovador lubricante en barra producido por la empresa japonesa Maia Co. Ltd. Este revolucionario lubricante sólido, que utiliza el polvo fino DURAST® POM de reciente lanzamiento, resuelve problemas como el goteo, las
More news about: Daicel Corporation High Performance Polymers SBU
Jun 21, 2026, 22:19 ET Daicel DURAST® POM-Feinpulver wird für innovatives Schmiermittel in Stiftform eingesetzt
Kunststoffen, hat bekannt gegeben, dass sein DURAST® POM-Feinpulver für den Einsatz in einem innovativen Schmiermittel in Stiftform des japanischen Herstellers Maia Co. Ltd. ausgewählt wurde. Dieses bahnbrechende Festschmiermittel nutzt das neu eingeführte DURAST® POM-Feinpulver, behebt Probleme wie Tropfen, Verspritzen
More news about: Daicel Corporation High Performance Polymers SBU
Jun 21, 2026, 21:26 ET La poudre fine de polyoxyméthylène (POM) DURAST® de Daicel retenue pour la fabrication d'un lubrifiant innovant sous forme de bâtonnet
poudre fine de POM DURAST® avait été retenue pour être utilisée dans un lubrifiant innovant sous forme de bâtonnet, produit par la société japonaise Maia Co. Ltd. Fabriqué à base de DURAST®, la poudre fine de POM récemment lancée sur le marché, ce lubrifiant solide révolutionnaire résout les problèmes
More news about: Daicel Corporation High Performance Polymers SBU
Jun 18, 2026, 07:00 ET Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark. "We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed
More news about: Compugen Ltd.
Jun 17, 2026, 13:26 ET Bayer apresenta soluções para o manejo de doenças e novidades no portifólio na 31ª Hortitec
inovadora. Investimos continuamente em tecnologias que auxiliem o produtor a enfrentar os desafios do campo com mais eficiência e segurança", afirma Fabio Maia, Gerente de Portfólio Frutas e Vegetais da Bayer. "O Valpura e o Xivana Smart são exemplos desse trabalho, oferecendo ferramentas eficientes para o manejo
More news about: Bayer
Jun 17, 2026, 08:42 ET Marc Butler Consulting Launches "Master Your Money" Credential
Butler is responding with the launch of Master Your Money Certified, a three-tier financial literacy credential program built on the 2026 MAIA finalist book Master Your Money, Secure Your Future. The same index finds Gen Z scoring just 38%, with 37% in the very-low literacy band
More news about: Marc Butler Consulting
Jun 17, 2026, 01:00 ET Daicel DURAST(R) POM Fine Powder Adopted for Innovative Stick-form Lubricant
engineering plastics, has announced that its DURAST(R) POM fine powder has been adopted for use in an innovative stick-form lubricant produced by Japan-based Maia Co. Ltd. This groundbreaking solid lubricant, utilizing newly launched DURAST(R) POM fine powder, resolves issues such as dripping, splattering, and
More news about: Daicel Corporation High Performance Polymers SBU
Jun 17, 2026, 01:00 ET Daicel DURAST(R) POM Fine Powder Adopted for Innovative Stick-form Lubricant
engineering plastics, has announced that its DURAST(R) POM fine powder has been adopted for use in an innovative stick-form lubricant produced by Japan-based Maia Co. Ltd. This groundbreaking solid lubricant, utilizing newly launched DURAST(R) POM fine powder, resolves issues such as dripping, splattering, and
More news about: Daicel Corporation High Performance Polymers SBU
Jun 16, 2026, 16:33 ET Maia Closes Seed Round to Accelerate AI-Powered Medical Coding and Revenue Cycle Management for Orthopaedic Practices
billing, including both E&M and surgical coding, denial appeals, and prior authorizations. Maia helps practices maximize accurate reimbursement, reduce denials, and cut administrative burden."Maia is delivering real value to orthopaedic groups across the country, and this round lets us move
More news about: Maia Medical Billing Corp
Jun 11, 2026, 07:00 ET Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark. Poster details: Title: MAIA-ovarian (NCT06888921)
More news about: Compugen Ltd.
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
https://www.researchsquare.com/article/rs-9407186/v1About MAIAThe Metabolism Agentic Intelligence Atlas (MAIA) is an nference strategic initiative focused on making cardiometabolism computable across therapies, diseases, organs, and patient trajectories. By integrating federated real-world data with AI-enabled clinical phenotyping, MAIA maps
More news about: nference
Jun 09, 2026, 01:59 ET XCMG CONNECT Hubungkan Pelanggan, Alat Berat, dan Lokasi Kerja Menjadi Sebuah Ekosistem Layanan Industri Digital
independen, Maia mewujudkan interaksi alami antara manusia dan mesin, layaknya seorang ahli teknik yang selalu mendampingi pelanggan.XCMG ONE merupakan aplikasi seluler yang dirancang khusus untuk pengguna internasional. Aplikasi ini mengintegrasikan fitur-fitur utama agen AI Maia yang mendorong
More news about: XCMG
Jun 08, 2026, 10:47 ET Kết nối mọi khách hàng, mọi thiết bị, mọi công trường: XCMG CONNECT tái định hình hệ sinh thái dịch vụ công nghiệp
dựngMaia, tác nhân AI thông minh đa ngôn ngữ và có khả năng cộng tác của XCMG, kết hợp học sâu với chuyên môn kỹ thuật để thực hiện các chẩn đoán thiết bị, phát hiện lỗi tự động và tối ưu hóa vận hành dựa trên dữ liệu. Có thể truy cập thông qua màn hình AI thông minh do XCMG tự phát triển, Maia mang
More news about: XCMG
Jun 08, 2026, 07:00 ET Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca
More news about: Compugen Ltd.
May 19, 2026, 21:15 ET Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
Protaigé delivers autonomous marketing execution at scale, with Maia running the platform on behalf of marketers from channels they already use.SINGAPORE, May 20, 2026 /PRNewswire/ --
More news about: Protaigé
May 19, 2026, 21:15 ET Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
Protaigé delivers autonomous marketing execution at scale, with Maia running the platform on behalf of marketers from channels they already use.SINGAPORE, May 19, 2026 /PRNewswire/ --
More news about: Protaigé
May 18, 2026, 07:00 ET Compugen Reports First Quarter 2026 Results
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig
More news about: Compugen Ltd.
May 15, 2026, 13:08 ET Growth Catalyst Group Appoints Maia Benson as Chief Commercial Officer
/PRNewswire/ -- Growth Catalyst Group of Companies (GCG), a global leader and investor in supply chain technology, today announced the appointment of Maia Benson as Chief Commercial Officer (CCO). Benson brings more than 20 years of experience building and scaling SaaS and logistics businesses in high-growth
More news about: Growth Catalyst Group
May 15, 2026, 13:01 ET Growth Catalyst Group Appoints Maia Benson as Chief Commercial Officer
/PRNewswire/ -- Growth Catalyst Group of Companies (GCG), a global leader and investor in supply chain technology, today announced the appointment of Maia Benson as Chief Commercial Officer (CCO). Benson brings more than 20 years of experience building and scaling SaaS and logistics businesses in high-growth
More news about: Growth Catalyst Group
May 12, 2026, 07:00 ET Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca
More news about: Compugen Ltd.
May 05, 2026, 09:00 ET ACE Venture Completes 51% Acquisition of Vireo Health New York, Uniting Corporate Infrastructure With Cultural Vision and Launching Boukét as New York's Premier Cannabis Lifestyle Brand
finance, law, design, entertainment, and experiential development, because the most enduring brands are built by the most intentional people. From Roy and Maia Nachum, the visionary minds behind Mercer Labs, shaping the physical experience of ACE dispensaries, to Craft Cartel founders Kenji Fujishima and Arthur
More news about: Boukét
May 04, 2026, 07:00 ET Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca
More news about: Compugen Ltd.
Apr 30, 2026, 15:49 ET Wegovy® é mais eficiente em preservar massa muscular durante a perda de peso, mostram novos estudos de vida real
qualidade, com menor comprometimento da massa magra e da função muscular, quando comparada à tirzepatida. Estudo divulgado em abril de 2026 pela iniciativa MAIA (Metabolism Agentic Intelligence Atlas), nos EUA, revela dados de vida real, com aproximadamente 8.000 pacientes com medidas de composição corporal
More news about: Novo Nordisk
Apr 28, 2026, 09:00 ET Dr. Leti Romo Joins Alliant University as Director of Inclusion & Community Relations
faculty who practice what they teach, a culture of belonging, and a track record of innovation across higher education.Media Contact:Maia Kelly-MolinaDirector of Strategic CommunicationsAlliant University
More news about: Alliant University